| P2093 | author name string | Yin JA | |
| | Macheta M | |
| P2860 | cites work | Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials. MRC Adult Leukaemia Working Party | Q74053090 |
| | Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients: graft-versus-host disease and transplant-related mortality | Q74593403 |
| | RT-PCR method with increased sensitivity shows persistence of PML-RARA fusion transcripts in patients in long-term remission of APL | Q77299316 |
| | Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B | Q28247684 |
| | All-trans-retinoic acid in acute promyelocytic leukemia | Q28250406 |
| | Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission | Q28290182 |
| | Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed | Q34567322 |
| | Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Par | Q34746103 |
| | On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group | Q35155166 |
| | Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organiz | Q36895799 |
| | A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study | Q39233227 |
| | Treatment of the elderly patient with acute myeloid leukaemia | Q40948245 |
| | Down-regulation of bcl-2 in AML blasts by all-trans retinoic acid and its relationship to CD34 antigen expression | Q41171514 |
| | Application of myeloid growth factors in the treatment of acute myeloid leukemia | Q41380555 |
| | Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia | Q42289001 |
| | Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantat | Q47956461 |
| | Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial. | Q50936772 |
| | Telomerase activity and telomere length in pediatric patients with malignancies undergoing chemotherapy. | Q52191382 |
| | The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer. Grup | Q54123667 |
| | A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial | Q55981048 |
| | Autologous peripheral blood stem cell transplantation (PBSCT) mobilized with G-CSF in AML in first complete remission. Role of intensification therapy in outcome | Q57221015 |
| | A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for B | Q71127546 |
| | Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study. MRC Leukaemia in Adults Working Party | Q71397114 |
| | Busulfan plus cyclophosphamide followed by autologous blood stem-cell transplantation for patients with acute myeloblastic leukemia in first complete remission: a report from a single institution | Q72229029 |
| | Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Ad | Q72377470 |
| | Marrow transplants from unrelated donors | Q72805692 |
| | P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival | Q72891082 |
| | Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle | Q73399570 |
| | Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients | Q73445645 |
| P433 | issue | 3 | |
| P304 | page(s) | 107-118 | |
| P577 | publication date | 2001-09-01 | |
| P1433 | published in | Hematological Oncology | Q15762617 |
| P1476 | title | Recent advances in the treatment of AML. | |
| P478 | volume | 19 | |